We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Watson’s Eden Biodesign and Crucell Sign Vendor Network Agreement Facilitating Access to cGMP Manufacturing Services for Vaccines and Gene Therapies Using PER.C6® Cell Line Technology

News   Nov 19, 2010

 
Watson’s Eden Biodesign and Crucell Sign Vendor Network Agreement Facilitating Access to cGMP Manufacturing Services for Vaccines and Gene Therapies Using PER.C6® Cell Line Technology
 
 
 

RELATED ARTICLES

AI Could Warn About Drug Interaction Side Effects

News

Researchers have designed an algorithm that analyzes data on drug-drug interactions listed in reports — compiled by the Food and Drug Administration and other organizations — for use in a possible alert system that would let patients know when a drug combination could prompt dangerous side effects.

READ MORE

Developing Pioneering Cell Therapies for Immunotherapy Non-responders

News

New research signposts a novel, less invasive method to identify killer T lymphocytes in patients with gastrointestinal tumors with low mutational burden who are refractory to currently-approved immune-based treatments.

READ MORE

Even Short-term Vaping Causes Inflammation in Non-smokers, Says Pilot Study

News

Researchers report the first evidence of biological changes correlated with e-cigarette use in never-smokers.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE